Protocol Ledger

NCT07440537 · Phase II · RECRUITING

Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study

Interventional Phase II clinical trial protocol NCT07440537 sponsored by Beijing InnoCare Pharma Tech Co in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-27 Enrollment: 105 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07440537
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)105 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07440537
Protocol FieldVerified Registry Value
NCT IdentifierNCT07440537
Consolidated Lead SponsorBeijing InnoCare Pharma Tech Co
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment105 participants (ESTIMATED)
Registered Start Date2026-04-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI